|Description||The assessment of the active thiopurine metabolites (6TGN & 6MMPN) of the thioguanine drugs azathioprine, 6-mercaptopurine and 6-thioguanine.|
|Indication||It is particularly relevant to determine the correct treatment regimes in patients who have TPMT heterozygous status who exhibit a low TPMT enzyme activity where reduced dose regimes are being used or where it is unclear that therapeutic levels are being achieved.|
|Additional Info||Please provide details of current thiopurine drug regime and patient diagnosis on the request form. PLEASE NOTE: Test is available to Bradford gastro, Leeds Paediatric oncology and Leeds Gastroenterology consultant requests.|
|Interpretation||235-450 pmol 6TGN/8x10^8 cells associated with maximum drug efficacy in inflammatory bowel disease.
>5700 pmol 6MMPN/8x10^8 cells associated with increased risk of hepatotoxicity.|
|Collection Conditions||Suggested that the level of 6TGN is checked 4 weeks after commencing/changing the thiopurine drug dose as by this time steady state levels should have been achieved. Time of sampling need not be related to the time of administration of the parent drug.|
|Ref. Range (Male)|| |
|Ref. Range (Female)|| |
|Ref. Range (Paed)|| |
|Ref. Range Notes||Units - pmol metabolite / 8x10^8 cells|
|Units|| - Not Defined -|
|IP Acute TAT||- Not Defined -|
|IP Routine TAT||7 days|
|GP Acute TAT||- Not Defined -|
|GP Routine TAT||7 days|
Originally edited by : RB. Review due on 02/06/2016 11:22:47. Published By RB on 02/06/2015 11:22:47.